ProPhase Labs, Inc.

PRPH Healthcare Diagnostics & Research

In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.

0.01 0.00 0.00%
Market cap
$1.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
4/9
Altman Z
−3.59
Beneish M
−4.90
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 4 4 3
ROE
(185.40%) (271.49%) (331.81%) (543.95%)
ROA
(52.95%) (23.96%) (44.22%) (45.53%)
ROIC
(220.98%) (122.44%) (203.72%) (387.30%)
Return on Tangible Assets
92.34% 30.78% 46.92% 42.01%
Average Days of Receivables
237.12 129.03 166.04 178.45
Free Cash Flow per Share
(2.54) (0.97) (0.46) (0.39)
Free Cash Flow
(10.55) (8.22) (5.63) (5.53)
Capital Expenditures
0.08 0.12 0.08 0.01
Other line items
Cash ROIC
(114.88%) (87.56%) (106.79%) (214.34%)
Accounts Receivable Turnover
0.29 0.40 0.31 0.29
Accounts Payable Turnover
0.14 0.11 0.09 0.09
Inventory Turnover
1.92 4.88 3.90 5.86
Average Days of Payables
3,754.80 4,999.92 6,436.61 5,998.92
Days of Inventory on Hand
23.87 8.63 10.79 9.68
Tax Rate
0.37 0.00 0.73 0.09
Research and Development Expense of Revenue
3.30% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
602.00% 444.74% 530.78% 514.92%
Share Based Compensation of Revenue
41.09% 43.57% 51.95% 51.62%
Interest Coverage
(7.28) (2.60) (2.41) (2.17)
Operating CF/Net income
0.25 0.57 0.24 0.24
Depreciation/Fixed assets
3.43 5.07 5.71 6.87
Capex/Depreciation
0.01 0.01 0.01 0.00
Revenue per Share
1.22 0.51 0.28 0.23
Operating CF per Share
(2.56) (0.98) (0.46) (0.40)
Capex per Share
0.02 0.01 0.01 0.00
Capex to Sales
(0.02) (0.03) (0.02) 0.00

Fold the line items

Columns are period end dates